PMID- 29230390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2296-4681 (Print)
IS  - 2296-4657 (Electronic)
IS  - 2296-4657 (Linking)
VI  - 3
IP  - 3
DP  - 2017 Sep
TI  - HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target?
PG  - 210-215
LID - 10.1159/000455871 [doi]
AB  - BACKGROUND: Retinoblastoma (RB) is the most common primary intraocular 
      malignancy. Current therapies are associated with high morbidity in the short- 
      and long-term. Human epidermal growth factor receptor 2 (HER2) is a transmembrane 
      protein detected in 15-30% of breast cancers, but it has also been described in 
      other malignancies. Recently, it has been claimed that a truncated version of 
      this protein is expressed in RB, responsive to directed therapies in vitro. We 
      scored HER2 overexpression in RB tissue samples and discussed its potential 
      clinical utility. METHODS: HER2 overexpression was investigated using 
      immunohistochemistry; the overexpression was evaluated with a score ranging from 
      0 to 3+ according to the membranous staining pattern in archival formalin-fixed, 
      paraffin-embedded RBs. RESULTS: A total of 60 RB cases and a RB cell line (Y79) 
      were considered. The mean age at enucleation was 31.6 +/- 31.5 months. The mean 
      time from diagnosis to enucleation was 11.8 +/- 11.2 months (range 1-44). Five (8%) 
      cases were multifocal. HER2 overexpression was negative in all RB cases (49 cases 
      scored 0 and 11 scored 1+) and in the Y79 cell line. CONCLUSIONS: Overall, we 
      were not able to demonstrate the overexpression of HER2. Further studies should 
      clarify and better elucidate the potential role of HER2-targeted therapies in RB.
FAU - Sousa, David Cordeiro
AU  - Sousa DC
AD  - Department of Ophthalmology, Hospital de Santa Maria, Lisbon, Portugal.
AD  - Centro de Estudos Ciencias da Visao, Universidade de Lisboa, Lisbon, Portugal.
FAU - Zoroquiain, Pablo
AU  - Zoroquiain P
AD  - MUHC - McGill University Ocular Pathology Laboratory, Montreal, Quebec City, 
      Canada.
FAU - Orellana, Maria Eugenia
AU  - Orellana ME
AD  - Instituto Anatomopatologico "Dr. Jose A. O'Daly", Universidad Central de 
      Venezuela, Caracas, Venezuela.
FAU - Dias, Ana Beatriz
AU  - Dias AB
AD  - MUHC - McGill University Ocular Pathology Laboratory, Montreal, Quebec City, 
      Canada.
FAU - Esposito, Evangelina
AU  - Esposito E
AD  - MUHC - McGill University Ocular Pathology Laboratory, Montreal, Quebec City, 
      Canada.
FAU - Burnier, Miguel N Jr
AU  - Burnier MN Jr
AD  - MUHC - McGill University Ocular Pathology Laboratory, Montreal, Quebec City, 
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20170223
PL  - Switzerland
TA  - Ocul Oncol Pathol
JT  - Ocular oncology and pathology
JID - 101656139
PMC - PMC5649335
OTO - NOTNLM
OT  - Anti-HER2 antibody
OT  - Human epidermal growth factor receptor 2
OT  - Immunohistochemistry
OT  - Retinoblastoma
OT  - Transmembrane protein
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:01
PMCR- 2018/09/01
CRDT- 2017/12/13 06:00
PHST- 2016/09/01 00:00 [received]
PHST- 2017/01/04 00:00 [revised]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:01 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - oop-0003-0210 [pii]
AID - 10.1159/000455871 [doi]
PST - ppublish
SO  - Ocul Oncol Pathol. 2017 Sep;3(3):210-215. doi: 10.1159/000455871. Epub 2017 Feb 
      23.